Medopad, Inc.

Medopad, Inc. specializes in self-care monitoring and reporting software, particularly tools designed for remote patient management and chronic condition tracking. Their products, such as the HUMA platform and Huma RPM system, focus on digital health solutions that allow users to monitor health metrics and generate reports independently. These are classified as software-based medical devices, enabling proactive health management.

Medopad, Inc. is headquartered in the United States, which means its devices fall under FDA jurisdiction. Since the company’s products are classified as Class II devices, they are subject to the FDA’s regulatory framework, including premarket notifications (510(k)) and unique device identification (UDI) requirements. The U.S. location also influences compliance with domestic regulations like the Medical Device Reporting (MDR) program and post-market surveillance standards.

Medopad, Inc.’s devices are listed in the FDA’s 510(k) and UDI registries. The 510(k) database tracks premarket submissions for Class II devices to demonstrate substantial equivalence to predicate products, ensuring safety and effectiveness before market entry. The UDI system assigns unique identifiers to devices for traceability, improving post-market surveillance and recall efficiency. Listing in these registries helps stakeholders verify compliance and access critical device information.

Medopad, Inc.’s devices are classified as FDA Class II, which is the second-highest risk category for medical devices. This classification implies that while the products pose moderate risk (e.g., through software-based monitoring), they require special controls beyond general controls to ensure safety and performance. Class II devices typically require premarket notifications (510(k)) to demonstrate equivalence to existing approved devices, though some may also undergo post-market surveillance to monitor long-term performance and adverse events.